Company (Symbol)*




Status (Date)**




Natural mixture of human cytokines, including interleukin-2

Advanced head and neck cancer

Presented results of Phase II trial in Poland and the Czech Republic at the Biotechnology Industry Organization's CEO & Investor Conference in New York (2/15)

Genzyme General (division of Genzyme Corp; GENZ) and Biobras SA (Brazil)

Thyrogen (FDA-approved)

Recombinant human thyroid stimulating hormone

Follow-up screening for patients who have been treated for thyroid cancer

Cleared for marketing in Brazil (2/2)

Medarex Inc.(MEDX), Immuno-Designed Molecules SA* and ImmunoDesigned Molecules Inc.*


Bispecific antibody that targets HER2 receptor

Ovarian cancer

Received European regulatory approval to initiate Phase III trial of MDX-210 in combination with IDM's Monocyte-derived Activated Killer (MAK) cell technology (2/14)

SuperGen Inc. (SUPG)

Rubitecan; oral chemotherapy compound in the camptothecin class

Pancreatic cancer

IND approved in Canada (2/4)


Active Biotech AB (Sweden; ACTIB)


Orally active immune response regulator

Multiple sclerosis

Reported results in initial portion of Phase I trial; Swedish medical products agency approved a more extensive study (2/12)

SkyePharma plc (UK; SKYE)


Sustained-release, encapsulated morphine sulfate (uses Depo-Foam, lipid-based drug delivery)

Hip replacement surgery

Announced Phase II trial results in Canada (2/22)


Generex Biotechnology Corp. (OTC BB: GNBT)


Oral insulin; administered as a fine spray into the oral cavity using a lightweight handheld aerosol applicator


Initiated trials in Engand comparing Oralin to subcutaneous insulin injection and placebo (3/9)


Advanced Viral Research Corp. (OTC BB: ADVR)

Substance R

Non-toxic peptide nucleic acid immuno-modulator

Viral infection

Received approval for Phase I trials in Argentina (2/18)

Bio-Technology General Corp. (BTGC)


Recombinant hepatitis B vaccine that integrates the S, pre-S1 and pre-S2 surface proteins of the virus

Prevention of hepatitis B infection

Cleared for marketing in Israel (2/14)

Enzon Inc. (ENZN) and Schering Plough Corp. (NYSE:SGP)


Long-acting dosage form of Schering's Intron A (recombinant interferon alfa-2b) conjugated to polyethylene glycol

Hepatitis C infection in adults

European Agency for the Evaluation of Medicinal Products issued recommended approval (2/22)

The Immune Response Corp. (IMNR) and Agouron Pharmaceuticals Inc. (subsidiary of Warner-Lambert Co. [NYSE: WLA])


Envelope-depleted, inactivated AIDS virus (emulsified with adjuvant)

HIV infection

Submitted Phase II trial data to the Thai Ministry of Health (2/23)

The Liposome Company Inc. (LIPO)


Complex of amphotericin B with two phospholipids

Invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B

Cleared for marketing in Lebanon (2/17)

PathoGenesis Corp. (PGNS)


Tobramycin solution for inhalation and AMRAD Pharmaceuticals Ptd. Ltd. (Australia)

Management of cystic fibrosis patients with Pseudomonas aeruginosa infections

Cleared for marketing in Australia (2/23)


Centocor Inc. and Schering-Plough Corp. (NYSE:SGP)

Remicade (FDA- approved)

Infliximab; chimeric monoclonal antibody to tumor necrosis factor alpha

Rheumatoid arthritis that has inadequately responded to dissease-modifying drugs; combination therapy with methotrexate

Committee for Proprietary Medicinal Products of the European Agency for the Evaluation of Medicinal Products recommended approval (2/23)

Genzyme General (GENZ) and GelTex Pharmaceuticals Inc. (GELX)

Renagel Capsules (FDA-approved)

Non-absorbed polymer-based compound that binds to and eliminates target substances from the intestinal tract


Cleared for marketing in the 15 member states of the European Union (2/3)

Immunex Corp. and Wyeth-Ayerst Pharmaceuticals (the pharmaceutical division of American Home Products Corp. [NYSE:AHP])

Enbrel (FDA-approved)

Entanercept; recombinant, soluble T75 tumor necrosis factor receptor (TNFr) linked to the Fc portion of human IgG1

Adult rheumatoid arthritis that inadequately responds to disease-modifying drugs

Cleared for marketing in 15 European Union countries by the European Medicines Evaluation Agency (2/7)


* Indicates a privately held company

** The dates listed indicate the issue dates of press releases, and are not necessarily the dates on which stated events took place.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SSE = Swedish Stock Exchange; TSE = Toronto Stock Exchange

ND = Not disclosed

IND = Investigational new drug application